NEW YORK, February 19, 2013 /PRNewswire/ --
Today, National Traders Association announced new research reports for Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), AstraZeneca plc. (NYSE: AZN) and Novartis AG (NYSE: NVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Pfizer Inc. Research Report
Viiv Healthcare Ltd., Pfizer's joint venture with two other drug makers, has issued a statement that the US Food and Drug Administration (FDA) has granted priority review status to the experimental HIV medicine dolutegravir. Priority status can be granted to drugs that offer significant improvement over existing treatments or to drugs that offer treatment for a disease that does not have any other type of cure. If the drug is approved, dolutegravir will be the second in a new type of HIV medicines called integrase inhibitors. Integrase inhibitors work by blocking the HIV's ability to replicate, therefore blocking the spread of the virus all over the body. This cutting-edge drug represents an opportunity for Pfizer to boost its pipeline given the market for HIV patients worldwide. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.nationaltradersassociation.org/r/full_research_report/bd2d_PFE
Johnson & Johnson Research Report
Janssen Research & Development, Johnson & Johnson's pharmaceutical company, has announced that the FDA has granted Breakthrough Therapy Designation for the investigational oral agent ibrutinib. The drug treats patients with B-Cell malignancies like relapsed or refractory mantle cell lymphoma (MCL) and Waldenstrom's macroglobulinemia (WM). The Breakthrough Therapy Designation speeds up the review time for a new type of medicine that can treat a serious or life-threatening disease or condition. Five thousand new MCL cases are reported every year, while 1,200 WM cases are reported each year, representing the potential market for Johnson & Johnson's ibrunitib. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.NationalTradersAssociation.org/r/full_research_report/b230_JNJ
Abbott Laboratories Research Report
Abbott has announced its 357th consecutive quarterly dividend at 14 cents per share, payable May 15, 2013. Earlier this year, Abbott announced that the FDA has approved its next-generation Xience Xpedition drug eluting stent system. Xpedition provides physicians with a trusted option to treat a broad range of patients suffering from coronary artery disease. With this product, physicians will have a new technology to reach blockage and restore blood flow with ease. Abbott's Xience line has been the bestselling stent for several years, generating $1 billion yearly for Abbott since 2009. Abbott's next product, the Absorb stent, is currently in clinical trials in the US and the company plans to file the product for regulatory approval by 2015. These unique products face minimal competition, giving Abbott a major share in the treatment of coronary artery diseases. The Full Research Report on Abbott Laboratories- including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.NationalTradersAssociation.org/r/full_research_report/b8f0_ABT
AstraZeneca plc. Research Report
AstraZeneca has announced that it will collaborate with N.N. Petrov Institute of Oncology, one of Russia's leading cancer institutions. Petrov Institute scientists will work with AstraZeneca's Oncology Innovative Medicines group at various centers worldwide to evaluate the role that genetic mutations play in developing cancer. Analysts believe that this collaboration will effectively boost the company's pipeline. Other efforts by the company to expand and diversify include collaborating with Isis Pharmaceuticals to develop a new generation antisense therapeutics against five cancer targets as well as acquiring Ardea, a biotechnology company with an ongoing gout program that has the potential to treat millions of patients worldwide. The Full Research Report on AstraZeneca plc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.NationalTradersAssociation.org/r/full_research_report/2770_AZN
Novartis AG Research Report
Novartis has favorable news to offer its investors. The company issued a statement saying that the FDA has approved Zortress, the first mTOR inhibitor drug that prevents organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation. The drug was also approved under the name Certican by European Health Authorities in the fourth quarter of 2012. At present, more than 6,000 liver transplants are performed in the United States each year, representing the potential market for Zortress. The drug is the first immunosuppressant approved by the FDA in over a decade for liver transplantation. Novartis' Exjade also received FDA approval earlier this year. The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.NationalTradersAssociation.org/r/full_research_report/5dc9_NVS
Consider National Traders Association
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Demi Lapierre
SOURCE National Traders Association